High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
Status:
Completed
Trial end date:
2017-09-20
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of gemcitabine,
busulfan, and melphalan, when given before a stem cell transplant, can help to control
refractory myeloma. The safety of this study treatment will also be studied.